| |
Newsroom /
Business
/
Markets
/
Biosimilars for Blood Disorder Indications in the US Will Reach More Than US$ 2.4 Billion in 2020
Biosimilars for Blood Disorder Indications in the US Will Reach More Than US$ 2.4 Billion in 2020
Biosimilar versions of Epogen (Epoetin Alfa) may be launched as early as 2013. This launch is expected to be followed by launches of biosimilar versions of Neupogen (Filgrastim) and Neulasta (Pegfilgrastim).
Noida,
Uttar pardesh,
India
(prbd.net)
17/11/2011
A study undertaken by IMARC Group entitled “Biosimilar/Follow-on Biologics Market Report & Forecast: A Focus on the US (2011-2020)” reveals that by 2020, biosimilars for blood disorder indications will reach sales worth more than US$ 2.4 billion in the US. Findings from the study suggest that biosimilar versions of Epogen (Epoetin Alfa) may be launched as early as 2013. This launch is expected to be followed by launches of biosimilar versions of Neupogen (Filgrastim) and Neulasta (Pegfilgrastim).
According to this study, biosimilar versions of Epogen and Neupogen have already been launched in major European markets with their uptake being quite promising in some of these markets. Historical generic adoption rates in the US have been significantly faster than most European markets, furthermore, a recent survey on US physicians suggested that respondents were quite willing to prescribe biosimilars for blood disorder indications upon their launch in the US. This suggests that the US penetration of biosimilars in the blood disorder indication would be even higher than the European levels.
IMARC’s new report entitled “Biosimilar/Follow-on Biologics Market Report & Forecast: A Focus on the US (2011-2020)” provides an analytical and statistical insight into the US biosimilar market. The study, that has been undertaken using desk-based as well as qualitative primary research, provides and draws upon analysis of six aspects of the US biosimilar market.
Key Aspects Analyzed:
Evaluating the Current Market Landscape of Biosimilars:
• Identification of currently marketed biosimilars and their historical performance
• Identifying the reasons for the slow uptake of currently marketed biosimilars
• Analyzing historical data to formulate conclusions on the future growth and market trends of biosimilars
Evaluating the Extent of Price, Sales and Volume Erosions Caused by Biosimilars:
• Analyzing historical time series data on price, volume and sales erosion in the US & Europe
• Analyzing previous models and assumptions on price and volume erosion caused by biosimilars
• Evaluating and comparing price and volume erosion created by biosimilars vis-a-vis by small molecule generics
• Evaluating and comparing price, volume and sales erosion by biosimilars across various biological classes
Evaluating the Market Potential of Biosimilars Across Various Molecules:
Molecules Covered: Somatropin (Genotropin/Humatrope/Other HGH), Epoetin Alfa (Epogen/Eprex), Filgrastim (Neupogen), Pegfilgrastim (Neulasta), Insulin Lispro (Humalog), Insulin Glargine (Lantus), Insulin Detemir (Levemir), Interferon Beta-1A (Avonex), Interferon Beta-1A (Rebif), Interferon Beta-1B (Betaferon), Bevacizumab (Avastin), Trastuzumab (Herceptin), Rituximab (Mabthera/Rituxan), Cetuximab (Erbitux), Etanercept (Enbrel), Infliximab (Remicade), Adalimumab (Humira), Ranibizumab (Lucentis), Omalizumab (Xolair) and Natalizumab (Tysabri).
Focus of the Analysis for Each Molecule:
• Historical background and overview
• Historical brand sales
• Patent position
• Competing products
• Biosimilars in pipeline
• Brand and biosimilar sales forecasts
Evaluating the Sales of Biosimilars across Various Indications:
Indications Covered: Immunology & Inflammation, Diabetes, Oncology, Blood Disorders and Growth Deficiency
Focus of the Analysis for Each Indication:
• Historical brand sales
• Brand and biosimilar sales forecasts
• Breakup of molecules
Evaluating the Biosimilar Competitive Landscape:
• Identifying branded biological manufacturers that expect the highest amount of erosion from biosimilars
• Identifying biosimilar manufacturers and their pipelines
Understanding the Current Legislation on Biosimilars:
• An insight into the Biologics Price Competition and Innovation Act
• An insight into the key biosimilar issues that still remain unaddressed
• Interchangeability and Substitutability
• Data Exclusivity
• Statutory provisions for dealing with patent litigations
Table of Contents
1 Market Definitions & Research Methodology
2 Executive Summary
3 The US Biosimilar Market Landscape
4 US Biosimilar Market: Current Experience
4.1 The Performance of Growth Hormone Biosimilars Has Been Dismal So Far
4.2 Pediatrics Represent the Prime Customer Base for Growth Hormones
4.3 Omnitrope Was Launched with an Inconvenient Delivery Device
4.4 Prescribing Patterns for Omnitrope
4.5 Uptake is Likely to Increase with the Accumulation of Post-Market Safety Data
5 US Biosimlar Market: How Much Price, Volume & Sales Erosion will Result
5.1 Omnitrope Cannot be Taken as a Benchmark to Gauge the Performance of Other Biosimilars
5.2 The European Uptake of ESA & GCSF Biosimilars Give Us a Very Positive Outlook for the US
5.3 Models for Biosimilar Volume Erosion Across Various Biological Classes
5.4 Models for Biosimilar Price Erosion Across Various Biological Classes
5.5 Models for Biosimilar Sales Erosion Across Various Biological Classes
6 US Biosimilar Market: Current Trends & Forecast by Drug
6.1 Growth Hormones
6.1.1 Somatropin (Genotropin/Humatrope/Other HGH)
6.2 Erythropoiesis Stimulating Agents
6.2.1 Epoetin Alfa (Epogen/Eprex)
6.3 Granulocyte Colony Stimulating Factor
6.3.1 Filgrastim (Neupogen)
6.3.2 Pegfilgrastim (Neulasta)
6.4 Insulin
6.41. Insulin Lispro (Humalog)
6.4.2 Insulin Glargine (Lantus)
6.4.3 Insulin Detemir (Levemir)
6.5 Interferons
6.5.1 Interferon Beta-1A (Avonex)
6.5.2 Interferon Beta-1A (Rebif)
6.5.3 Interferon Beta-1B (Betaferon/Betaseron)
6.6 TNF Alpha & Monoclonal Antibodies (Immunology & Inflammation)
6.6.1 Etanercept (Enbrel)
6.6.2 Infliximab (Remicade)
6.6.3 Adalimumab (Humira)
6.6. Ranibizumab (Lucentis)
6.6. Omalizumab (Xolair)
6.6.6 Natalizumab (Tysabri)
6.7 Monoclonal Antibodies (Oncology)
6.7.1 Bevacizumab (Avastin)
6.7.2 Trastuzumab (Herceptin)
6.7.3 Rituximab (Mabthera)
6.7.4 Cetuximab (Erbitux)
7 US Biosimilar Market: Current Trends & Forecast by Indication
7.1 Immunology & Inflammation
7.1.1 Current Trends & Forecast
7.1.2 Biosimilar Sales Breakup by Molecule
7.2 Diabetes
7.2.1 Current Trends & Forecast
7.2.2 Biosimilar Sales Breakup by Molecule
7.3 Oncology
7.3.1 Current Trends & Forecast
7.3.2 Biosimilar Sales Breakup by Molecule
7.4 Blood Disorders
7.4.1 Current Trends & Forecast
7.4.2 Biosimilar Sales Breakup by Molecule
7.5 Growth Deficiency
7.5.1 Current Trends & Forecast
7.5.2 Biosimilar Sales Breakup by Molecule
8 Competitive Landscape
8.1 Branded Manufacturers: Companies Facing the Highest Amount of Biosimilar Erosion
8.2 Biosimilar Manufacturers: Companies Gaining the Most From Biosimilar Launches
9 Biosimilar Legislation in the US
9.1 The Biologics Price Competition and Innovation Act: An Insight
9.2 Biosimilar Issues that Still Remain Unaddressed
9.3 Major Issues Impacting the Business Strategies of Biological Companies
9.3.1 Interchangeability & Substitutability
9.3.2 Data Exclusivity
9.3.3 Patent Litigation
10 Key Company Profiles
10.1 Teva Pharmaceutical Industries Ltd.
10.2 Sandoz, Inc.
10.3 Hospira, Inc.
10.4 STADA Arzneimittel AG
10.5 Dr. Reddy's Laboratories Ltd.
10.6 Celltrion, Inc.
10.7 Bioexpress Therapeutics SA
To buy the complete report or to get a free sample, please contact:
IMARC Group Asia
Email: apac@imarcgroup.com
Phone: +91-120-425-6531
IMARC Group North America
Email: america@imarcgroup.com
Phone: +1-631-791-1145
To know more please visit: http://www.imarcgroup.com/
About
For more than 5 years, the International Market Analysis Research and Consulting Group has been a leading advisor on management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
|